• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data.

作者信息

Athyros Vasilios G, Stavropoulos Konstantinos, Imprialos Konstantinos P, Doumas Michael

机构信息

2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece.

2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece.

出版信息

Int J Cardiol. 2020 Oct 1;316:240-241. doi: 10.1016/j.ijcard.2020.06.059. Epub 2020 Jul 4.

DOI:10.1016/j.ijcard.2020.06.059
PMID:32634493
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7334918/
Abstract
摘要

相似文献

1
Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data.日常临床实践中血脂异常的管理欠佳：来自真实世界数据的警示信号。
Int J Cardiol. 2020 Oct 1;316:240-241. doi: 10.1016/j.ijcard.2020.06.059. Epub 2020 Jul 4.
2
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.低密度脂蛋白胆固醇≥190mg/dL患者降脂治疗使用情况的差异：来自国家心血管数据注册库 - 实践创新与临床卓越注册库的见解
Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652.
3
Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.美国接受他汀类药物治疗成年人中根据低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B划分的残余血脂异常：2009 - 2010年美国国家健康和营养检查调查
J Clin Lipidol. 2015 Jul-Aug;9(4):525-32. doi: 10.1016/j.jacl.2015.05.003. Epub 2015 May 16.
4
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.在高和极高心血管风险患者中使用调脂治疗和降低低密度脂蛋白胆固醇目标达标情况：来自德国的真实世界证据。
Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20.
5
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.在高或极高心血管风险患者中他汀类药物的应用和血脂目标达标情况：来自意大利普通实践的见解。
Atherosclerosis. 2018 Apr;271:120-127. doi: 10.1016/j.atherosclerosis.2018.02.024. Epub 2018 Feb 17.
6
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估：临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
7
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常：一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
8
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).18 个西欧以外国家的低密度脂蛋白胆固醇目标达标情况：国际胆固醇管理实践研究（ICLPS）。
Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094. doi: 10.1177/2047487318777079. Epub 2018 May 17.
9
Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.降脂治疗与中国福州高危心血管风险患者的低密度脂蛋白胆固醇（LDL-C）目标达标情况。
J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):307-315. doi: 10.1177/1074248419899298. Epub 2020 Jan 10.
10
Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).心血管临床实践中低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇目标的达成频率（来自国家心血管数据注册库PINNACLE注册研究）
Am J Cardiol. 2015 Aug 15;116(4):547-53. doi: 10.1016/j.amjcard.2015.05.011. Epub 2015 May 21.

引用本文的文献

1
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia.沙特阿拉伯急性冠状动脉综合征患者血脂管理的前瞻性评估。
Saudi Med J. 2023 Jun;44(6):570-579. doi: 10.15537/smj.2023.44.6.20230023.
2
Prevalence and management of hypercholesterolemia in France, the Esteban observational study.法国高胆固醇血症的流行情况和管理：Esteban 观察性研究。
Medicine (Baltimore). 2020 Dec 11;99(50):e23445. doi: 10.1097/MD.0000000000023445.

本文引用的文献

1
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.当前脂质降低治疗以及欧洲心脏病学会/欧洲动脉粥样硬化学会（ESC/EAS）指南推荐的已确诊动脉粥样硬化性心血管疾病的极高危患者低密度脂蛋白（LDL）目标的达成情况：来自START注册研究的见解
Int J Cardiol. 2020 Oct 1;316:229-235. doi: 10.1016/j.ijcard.2020.05.055. Epub 2020 May 26.
2
Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data.高血压患者胆固醇管理中的终生风险评估：基于电子健康记录数据的观察性横断面研究。
BMC Fam Pract. 2020 Apr 14;21(1):62. doi: 10.1186/s12875-020-01138-5.
3
Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS).降脂治疗患者在西欧和北美以外地区的医疗资源利用情况：国际胆固醇管理实践研究（ICLPS）的横断面观察研究结果。
Lipids Health Dis. 2020 Apr 7;19(1):64. doi: 10.1186/s12944-020-01235-5.
4
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.2019 年 ESC/EAS 血脂异常指南在近期心肌梗死患者全国数据中的应用：一项模拟研究。
Eur Heart J. 2020 Oct 21;41(40):3900-3909. doi: 10.1093/eurheartj/ehaa034.
5
A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南的临床视角：PCSK-9抑制剂适用于所有人吗？
Eur Heart J. 2020 Jun 21;41(24):2331. doi: 10.1093/eurheartj/ehaa005.
6
Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea.韩国血脂异常患者的低密度脂蛋白胆固醇目标达标情况。
PLoS One. 2020 Jan 30;15(1):e0228472. doi: 10.1371/journal.pone.0228472. eCollection 2020.
7
Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study.韩国心血管疾病和糖尿病高危患者的低密度脂蛋白胆固醇目标达标率：一项回顾性队列研究。
Lipids Health Dis. 2020 Jan 11;19(1):5. doi: 10.1186/s12944-019-1158-5.
8
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.
9
Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries.简化风险因素记录与控制的审核：一项在11个国家开展的国际研究报告
Eur J Prev Cardiol. 2016 Jul;23(11):1202-10. doi: 10.1177/2047487316647827. Epub 2016 Apr 26.
10
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.欧洲动脉粥样硬化调查项目IV：欧洲心脏病学会对来自24个欧洲国家的冠心病患者的生活方式、危险因素及治疗管理情况的调查。
Eur J Prev Cardiol. 2016 Apr;23(6):636-48. doi: 10.1177/2047487315569401. Epub 2015 Feb 16.